News und Analysen
Pfizer Prices $31,000,000,000 Debt Offering
Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the pricing of a debt offering consisting of eight tranches of notes (collectively, the “Notes”):
$3,000,000,000 aggregate principal amount of
Agilent Wins SEAL Award for Innovative Products that Help Customers Achieve Their Sustainability Goals
Agilent Technologies Inc. (NYSE: A) today received a SEAL Business Sustainability Award for producing products and technology that are helping analytical and clinical labs reduce their carbon
Pfizer Announces Proposed Notes Offering
Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd. (the “Issuer”), has commenced a multi-series offering of senior
Humana to Partner with Two National Durable Medical Equipment Organizations
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it has reached agreement with two national organizations to provide Durable Medical Equipment (DME) services to
Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Humana and Longevity Health Partner to Expand Access to Special Needs Plans for Medicare Beneficiaries
Longevity Health Plan and Humana Inc. (NYSE: HUM) today announced a new partnership to expand special needs health plan offerings that support the unique requirements of Medicare-eligible
Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye
Agilent Technologies Inc. (NYSE: A) announced today that Dr. Jiangbin Ye has received an Agilent Solutions Innovation Research Award (SIRA). The award supports drug discovery and development
QuidelOrtho Reports First Quarter 2023 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028
DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private
Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a study “Cost-Effectiveness of a
Agilent to Announce Second-Quarter Fiscal Year 2023 Financial Results May 23
Agilent Technologies Inc. (NYSE: A) will release financial results and hold an earnings conference call for the second quarter of fiscal year 2023 after the stock market closes on Tuesday, May 23
Pfizer Declares Second-Quarter 2023 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company’s common stock, payable June 9, 2023, to holders of the Common Stock
Pfizer Reports First-Quarter 2023 Results
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2023 and reaffirmed full-year 2023 financial guidance.
The first-quarter 2023 earnings presentation and accompanying
Dexcom Reports First Quarter 2023 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023.
First Quarter 2023 Financial Highlights:
-
Revenue grew 18% versus the same
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive